Empirico Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 72

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $69.2M

  • Investors
  • 5

Empirico General Information

Description

Developer of siRNA-based therapeutics designed to target and treat diseases by leveraging naturally occurring genetic variants. The company offers proprietary platforms for genetically validated target discovery and siRNA drug development, enabling pharmaceutical and biotechnology partners to advance treatments for patients with unmet medical needs.

Contact Information

Website
www.empiri.co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10955 Vista Sorrento Parkway
  • Suite 130
  • CA 92130
  • United States
+1 (347)
Primary Industry
Biotechnology
Corporate Office
  • 10955 Vista Sorrento Parkway
  • Suite 130
  • CA 92130
  • United States
+1 (347)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Empirico Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 20-Mar-2023 $69.2M Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A2) 20-Dec-2019 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 01-Nov-2018 $12.5M $12.5M Completed Pre-Clinical Trials
To view Empirico’s complete valuation and funding history, request access »

Empirico Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-1
Series B
Series A2
Series A1 426,540 $0.000010 $0.1 $1.29 $1.29 1x $1.29 1.02%
Series A 7,445,092 $0.000010 $0.13 $1.61 $1.61 1x $1.61 17.8%
To view Empirico’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Empirico Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of siRNA-based therapeutics designed to target and treat diseases by leveraging naturally occurring genetic va
Biotechnology
CA
72 As of 2025

Pasadena, CA
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Empirico Competitors (7)

One of Empirico’s 7 competitors is Arrowhead Pharmaceuticals, a Corporation company based in Pasadena, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA
Silence Therapeutics Formerly VC-backed London, United Kingdom
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA
You’re viewing 5 of 7 competitors. Get the full list »

Empirico Patents

Empirico Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222326-A1 Treatment of lung related diseases and disorders Pending 17-Apr-2025
WO-2026193191-A2 Modified oligonucleotides Pending 13-Mar-2025
WO-2026164975-A1 Treatment of plg related diseases and disorders Pending 28-Jan-2025
WO-2026122565-A1 Treatment of fgg related diseases and disorders Pending 04-Dec-2024
WO-2026090085-A1 Treatment of cd33 related diseases and disorders Pending 21-Oct-2024 A61P25/28
To view Empirico’s complete patent history, request access »

Empirico Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Empirico Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbCellera Biologics Corporation Minority
Qiming Venture Partners USA Venture Capital Minority
Ionis Pharmaceuticals Corporation Minority
DCVC Bio Venture Capital Minority
Neotribe Ventures Venture Capital Minority
To view Empirico’s complete investors history, request access »

Empirico FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process